Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07258446 · ClinicalTrials.gov registry record · NA
PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma
A NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8, sponsored by University of California, Davis.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT07258446: Recruiting NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8, sponsored by University of California, Davis.
NCT07258446 is a NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8 that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 36 participants, below the 504-participant average among 4 other Clinical Stage I Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07258446, a NA study of Clinical Stage I Cutaneous Melanoma AJCC v8 and Clinical Stage II Cutaneous Melanoma AJCC v8, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage 0 to IIc cutaneous melanoma. SMMS is a method of skin cancer removal involving repeated tissue removal and examination under a microscope to ensure the tumor is removed as much as possible while sparing healthy tissue. In SMMS, tissue sections are evaluated to determine whether additional tissue removal is needed. The standard method for evaluating the tissue is by using a specific stain called hematoxylin and eosin (H\&E) stains. PRAME is a cancer antigen that is being investigated as a diagnostic marker in certain types of cancer. Adding PRAME IHC analysis to standard SMMS staining methods may improve the accuracy for determining whether additional tissue removal is necessary for patients undergoing SMMS for stage 0 to IIc cutaneous melanoma.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Immunohistochemistry Staining Method
- PROCEDURE Mohs Surgery
Study Locations (1)
California
- University of California Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2033-11-01 |
| Phase | NA |
What NCT07258446 shows while recruiting
NCT07258446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 504-participant average among 4 other Clinical Stage I Cutaneous Melanoma AJCC v8 trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Clinical Stage I Cutaneous Melanoma AJCC v8 appearing as the primary indexed condition, and to 2 interventions - of which Immunohistochemistry Staining Method is the first listed.
NCT07258446 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07258446 about?
NCT07258446 is a clinical study titled "PRAME Immunohistochemistry-Guided Slow Mohs Micrographic Surgery for the Treatment of Stage 0 to IIc Cutaneous Melanoma". This clinical trial tests the addition of preferentially expressed antigen in melanoma (PRAME) immunohistochemical (IHC) staining to standard slow Mohs micrographic surgery (SMMS) for guiding tissue removal in patients with stage 0 to IIc cutaneous melanoma. SMMS is a method of skin cancer removal i...
What is the current status of trial NCT07258446?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2025-10-24. Estimated completion is 2033-11-01.
What conditions does trial NCT07258446 study?
This clinical trial studies the following conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage 0 Cutaneous Melanoma AJCC v8.
What interventions are being tested in trial NCT07258446?
The interventions under investigation include: Immunohistochemistry Staining Method (DIAGNOSTIC_TEST), Mohs Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT07258446?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07258446 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage I Cutaneous Melanoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
ACTIVE NOT RECRUITING · NA
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
RECRUITING · Phase 1
-
The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI